PURPOSE: : To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. METHODS: : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated with a topical form of carbonic anhydrase inhibitor. Examinations performed before and during treatment included best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study charts and contrast sensitivity measured with briefly presented grating targets and the Pelli-Robson letter contrast sensitivity chart, microperimetry, and spectral-domain optical coherence tomography. RESULTS: : The 2 choroideremia patients treated with dorzolamide 2% formulation had a noticeable reduction in macular thickness by spectral-domain optical coherence tomography. This reduction was found in both eyes after 2 months of treatment. After an additional 3 months of the same treatment regimen, a more noticeable reduction in macular thickness was observed. The two study patients had improvement of their visual acuity, in at least one eye, on Early Treatment Diabetic Retinopathy Study charts, but no clinically significant changes for the other measures of visual function. CONCLUSION: : The present study shows the potential efficacy of topical dorzolamide for treating choroideremia patients with cystoid macular edema.
PURPOSE: : To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremiapatients with cystoid macular edema. METHODS: : Two choroideremiapatients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated with a topical form of carbonic anhydrase inhibitor. Examinations performed before and during treatment included best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study charts and contrast sensitivity measured with briefly presented grating targets and the Pelli-Robson letter contrast sensitivity chart, microperimetry, and spectral-domain optical coherence tomography. RESULTS: : The 2 choroideremiapatients treated with dorzolamide 2% formulation had a noticeable reduction in macular thickness by spectral-domain optical coherence tomography. This reduction was found in both eyes after 2 months of treatment. After an additional 3 months of the same treatment regimen, a more noticeable reduction in macular thickness was observed. The two study patients had improvement of their visual acuity, in at least one eye, on Early Treatment Diabetic Retinopathy Study charts, but no clinically significant changes for the other measures of visual function. CONCLUSION: : The present study shows the potential efficacy of topical dorzolamide for treating choroideremiapatients with cystoid macular edema.
Authors: Elliott H Sohn; Fred K Chen; Gary S Rubin; Anthony T Moore; Andrew R Webster; Robert E MacLaren Journal: Ophthalmology Date: 2010-02-19 Impact factor: 12.079
Authors: André Luís Carvalho de Moura Bastos; Bruno de Paula Freitas; Oscar Villas Boas; Alexandre Campelo Ramiro Journal: Arq Bras Oftalmol Date: 2008 Mar-Apr Impact factor: 0.872
Authors: Jennifer H Acton; R Theodore Smith; Donald C Hood; Vivienne C Greenstein Journal: Invest Ophthalmol Vis Sci Date: 2012-11-09 Impact factor: 4.799
Authors: Jason Hsu; Samir N Patel; Jeremy D Wolfe; Chirag P Shah; Eric Chen; Thomas L Jenkins; Turner D Wibbelsman; Anthony Obeid; Mikel Mikhail; Sunir J Garg; Allen C Ho; Allen Chiang; Marc J Spirn; James F Vander Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald Journal: Expert Opin Orphan Drugs Date: 2015-07-01 Impact factor: 0.694